卡格列净
医学
达帕格列嗪
恩帕吉菲
截肢
糖尿病
不利影响
血糖性
重症监护医学
内科学
安慰剂
外科
2型糖尿病
内分泌学
病理
替代医学
作者
A Misher,Andrea Ampuero,Rebecca Phan,Soma Aziz,Eti Ebong,Judy Braich,Kristin Dyches,Robin Southwood
出处
期刊:American Journal of Therapeutics
日期:2020-03-18
卷期号:28 (1): e96-e110
被引量:2
标识
DOI:10.1097/mjt.0000000000001164
摘要
Background: Diabetes mellitus is a major cause of morbidity and mortality in the United States. Twelve medication classes on the market reduce serum glucose including sodium–glucose cotransporter-2 (SGLT2) inhibitors. Potential benefits of these agents include improved glycemic control, weight loss, reduction in blood pressure, and possible reduction in cardiovascular events in patients with elevated cardiovascular risk. Areas of Uncertainty: Recently, several adverse events have been identified including increased possible risk of amputation associated with SGLT2 inhibitor therapy. Data Source: We conducted a review of published literature and identified 32 trials reviewing incidence of SGLT2 inhibitor-related amputation. Results: The potential increased risk for amputation is mostly of the lower extremities. Of the SGLT2 inhibitors currently available, canagliflozin has the highest association with an increased risk of lower extremity amputation and is the only agent with a Food and drug Administration Black Box Warning. Most canagliflozin amputation occurred in a single study. Risk factors for amputation with SGLT2 inhibitors may include those who have a history of amputations, susceptible to foot ulcers and those with baseline cardiovascular disease. Conclusions: For at-risk patients who desire an agent from this drug class, empagliflozin or dapagliflozin should be considered, as studies have not found a significant increase in amputations when compared with placebo or in retrospective reviews. Despite the increased risk of amputation found with canagliflozin, providers can use SGLT2 inhibitors with frequent monitoring to safely manage diabetes in low-risk patients. Patient education on associated risks is warranted. Diabetes educators can inform patients of risk factors to assist with monitoring.
科研通智能强力驱动
Strongly Powered by AbleSci AI